Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab + Bevacizumab + CAPOX/mCAPIRI in Advanced Colorectal Cancer
NCT07446387Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- May 2026
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab, tuvonralimab in colorectal cancer (CRC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Planned start May 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07446387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07446387.